Vaxcyte (PCVX) Shares Outstanding (2019 - 2026)

Vaxcyte (PCVX) has reported Shares Outstanding (Entity) for 8 consecutive years, with $144.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Shares Outstanding (Entity) rose 11.92% year-over-year to $144.3 million; the TTM figure through Mar 2026 stood at $144.3 million (up 11.92% YoY), while the FY2025 annual figure was $131.1 million, up 4.94% from the prior year.
• Shares Outstanding (Entity) rose to $144.3 million in Q1 2026 per PCVX's latest filing, from $131.1 million in the prior quarter.
• Across five years, Shares Outstanding (Entity) topped out at $144.3 million in Q1 2026 and bottomed at $56.5 million in Q1 2022.
• Historically, Shares Outstanding (Entity) has averaged $102.3 million across 5 years, with a median of $108.8 million in 2024.
• Annual changes were most pronounced in 2023 — Shares Outstanding (Entity) soared 60.02% — and 2025, when it grew 4.5%.
• Vaxcyte's Shares Outstanding (Entity) stood at $64.9 million in 2022, then surged by 46.99% to $95.4 million in 2023, then jumped by 30.96% to $124.9 million in 2024, then gained by 4.94% to $131.1 million in 2025, then grew by 10.11% to $144.3 million in 2026.
• Business Quant data shows PCVX's Shares Outstanding (Entity) at $144.3 million in Q1 2026, $131.1 million in Q4 2025, and $130.0 million in Q3 2025.